Enovis Corp Stock Price, News & Analysis

Enovis (NYSE: ENOV) has announced it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2024 financial results on Wednesday, February 26th, 2025 at 8:30 a.m. Eastern Time. The company will release its earnings press release earlier that morning.

A presentation related to the call will be accessible from the 'Investors' section of Enovis' website. Investors can participate by dialing (833) 685-0901 for U.S. callers and (412) 317-5715 for International callers. A replay of the call will be available on the company's website later that day.

Enovis (NYSE: ENOV) has announced a leadership transition in its International Surgical Business. Davide Visentin will succeed Dr. Benjamin Reinmann as President, effective March 1, 2025. Visentin brings over 20 years of healthcare experience, most recently serving as VP and General Manager at BD's Integrated Diagnostic Solutions, where he managed 700+ employees across 50 countries.

Prior to BD, Visentin held leadership positions at Stryker's Joint Replacement and Robotic Division and Johnson & Johnson Depuy Synthes. He holds a Computer Science degree from the University of Milan and will primarily operate from Villanova, Italy, and Bettlach, Switzerland.

The company highlighted its progress in building its International Surgical Business, emphasizing its commitment to market share growth and innovation in global orthopedics.

Enovis (NYSE: ENOV), a medical technology growth company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will present on Monday, January 13th, 2025, at 9:45 a.m. PST (12:45 p.m. EST).

Investors and interested parties can access the live audio webcast, presentation slides, and event replay through the Events and Presentations section of the company's website at www.enovis.com.

Enovis (NYSE: ENOV) has announced its management team's participation in two upcoming investor conferences. At the Jefferies London Healthcare Conference, Chair and CEO Matt Trerotola and CFO Ben Berry will join a fireside chat on November 20th at 12:00 p.m. GMT. Subsequently, CFO Ben Berry will participate in the Evercore 7th Annual HealthCONx Conference on December 4th at 10:50 a.m. ET.

Both events will be available via live audio webcasts and replays on the company's website under the Investors tab. Enovis is a medical technology growth company focused on developing clinically differentiated solutions for better patient outcomes and workflow transformation in orthopedics and beyond.

Enovis (ENOV) reported third-quarter 2024 results with net sales of $505 million, showing 21% growth on a reported basis and 6% on a comparable basis. The company's Reconstructive segment grew 57% reported (9% comparable), while P&R grew 1% reported (3% comparable). Despite reporting a net loss from continuing operations of $34 million ($0.61 per share), adjusted earnings were $0.73 per share, up 30% Y/Y. Adjusted EBITDA reached $90 million or 17.9% of sales. The company narrowed its 2024 revenue guidance to $2.10 billion and adjusted EBITDA to $373-$378 million, while raising full-year adjusted EPS guidance to $2.75-$2.80.

Enovis (NYSE: ENOV), a medical technology growth company, has announced it will host an investor conference call and live webcast to discuss its third quarter 2024 financial results on Wednesday, November 6th, 2024 at 8:30 a.m. Eastern Time. The company will issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com.

Investors can access the live webcast via a link on the Enovis website. Those planning to participate on the call should dial (833) 685-0901 (U.S. callers) and (412) 317-5715 (International callers) and ask to join the Enovis call. A replay of the call will be available on the Enovis website later that day.

Enovis (NYSE: ENOV) has appointed Tim Czartoski as President of U.S. Surgical and Global Product and Enabling Technologies. Czartoski, who reports to Louie Vogt, Group President of Enovis' Reconstructive Business Group, brings over 22 years of experience from Depuy Synthes, Johnson & Johnson's Orthopaedics Company. In his previous role, he led Depuy Synthes' U.S. operations, overseeing joint reconstruction, trauma, spine, digital technology, capital, sports, and CMF businesses.

Czartoski's appointment is expected to accelerate Enovis' growth potential and strengthen its surgical pipeline globally. His educational background includes a B.S. from Ohio State University, an M.S. in Technology Management from Columbia, and an MBA from Notre Dame.

Enovis™ (NYSE: ENOV), a medical technology company, is set to unveil its new Tarsoplasty Percutaneous Lapidus System and offer live demonstrations of Better Step, a patient-focused platform, at the American Orthopaedic Foot & Ankle Society® (AOFAS) annual meeting from September 11–14, 2024, in Vancouver. The Tarsoplasty system aims to reduce operative time and improve patient recovery outcomes for bunionectomy procedures. Better Step enhances the patient experience throughout bunion surgery recovery. Enovis will also showcase other advanced solutions, including the DynaNail® TTC Fusion System, Evolve34™ Lapidus Correction System, and expanded options for the Arsenal Foot Plating System.

Enovis (NYSE: ENOV) has expanded its EMPOWR Revision Knee™ system with the addition of EMPOWR™ Cones, creating a comprehensive portfolio for complex revision knee surgeries. The FDA-cleared cones include stackable tibial, femoral, and diaphyseal options to treat bone defects. This expansion aims to redefine revision knee arthroplasty by offering a streamlined yet comprehensive setup, reducing operating room clutter while allowing surgeons to fine-tune implant fit.

The system's features include femoral and tibial stackable augments usable both medially and laterally, minimizing excess inventory. Multifunctional instrumentation keeps the surgeon's back table organized, streamlining procedures. The addition of EMPOWR Cones provides surgeons with greater flexibility in tailoring revision surgeries, addressing a market need for more efficient revision options, particularly with growing interest in outpatient procedures.